[New trends in non-Hodgkin's lymphoma therapy]

Abstract

Non-Hodgkin's lymphomas are a heterogeneous group of lymphoid malignancies. Although great progress in the treatment of these diseases has been made in the last years, it is still difficult to achieve and sustain remission in different lymphoma subtypes and some of patients have poor prognosis. Apart from monoclonal antibodies, radioimmunotherapy, and autologous stem cell transplantation, which are used as standard therapy for some lymphomas, new drugs with different mechanism of action are currently being tested. This article describes new methods and drugs which are used in the treatment of non-Hodgkin's lymphomas.